FOLLOWING its recent acquisition of UK-firm EMMAC Life Sciences leading US player Curaleaf has wasted no time in expanding into Europe’s biggest medical cannabis market.
Curaleaf International (formerly EMMAC), through its wholly owned subsidiary Adven has launched its own range of medical cannabis products into Germany.
It says the initial product launch of a high-THC oil product will be extended over the next few months to incorporate a number of different strengths and THC/CBD formulations in both oils and flower.
Adven Managing Director Julian Vaterrodt said: “German patients and practitioners are increasingly demanding high-quality, consistent and reliable European natural alternatives to help manage a wide range of complaints.
“Adven is committed to providing a differentiated product and service for the German market.”
Antonio Costanzo, CEO of Curaleaf International, added: “Curaleaf International’s European supply chain, from cultivation to product research and development and EU-GMP manufacturing processes across Europe, means we are able to guarantee a consistency of product and price to clinicians and patients in need of the highest quality medical cannabis.”
In its recent sixth European Cannabis Report Prohibition Partners estimates Germany had 128,000 active patients at the end of 2020.
Its medical cannabis products are currently sourced from a wide range of countries including Canada, Netherlands, Uruguay, Portugal, Israel, Spain and Australia.
